Company
SynOx Therapeutics Ltd
SynOx Therapeutics is a clinical-stage company focused on developing emactuzumab, a differentiated, next-generation monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.
Also known as SynOx Therapeutics
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Founded
- 2020
- Legal name
- SynOx Therapeutics Ltd
Claim, correct or request removal
Record updated 28 September 2026
About
SynOx Therapeutics is a clinical-stage company focused on developing emactuzumab, a differentiated, next-generation monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.
Products
- Other
- emactuzumab
Loading relationship preview